Nutex Health (NASDAQ:NUTX) management highlighted sharp full-year revenue and earnings growth in 2025, improved cash generation, and continued progress navigating reimbursement under the Independent Dispute Resolution (IDR) process, while acknowledging a one-time fourth-quarter revenue reduction tied to arbitration claims deemed ineligible.
Full-year 2025 results: revenue up 82% and adjusted EBITDA more than doubles
Chairman and CEO Dr. Tom Vo said 2025 reflected “exceptional growth, operational discipline, and continued innovation,” with the company returning to profitability levels consistent with its historical micro-hospital model.
Adjusted EBITDA, which adds back stock-based compensation, rose to $259.6 million, up 152.6% from $102.8 million in 2024.
Operationally, hospital visits increased 11.8% to 188,279 from 168,388 in 2024. Management said mature facilities contributed 1.3% growth, which it characterized as evidence of resilience.
Fourth quarter affected by one-time $55 million arbitration true-up
In the fourth quarter, Nutex recorded what Vo described as a one-time $55 million revenue reduction related to the cumulative true-up of 18,950 arbitration claims deemed ineligible under the IDR process. The company said the reconciliation covered claims submitted from July 2024 through December 2025 and was driven by a mid-2025 CMS directive instructing certified IDR entities to clear dispute backlogs.
Bates said reported fourth-quarter revenue decreased 41.1% to $151.7 million versus $257.6 million in the year-ago quarter, attributing the decline primarily to the $55 million true-up and a separate comparison item: $69 million of arbitration revenue recorded in fourth-quarter 2024 that related to third-quarter 2024 submissions. Excluding the adjustments, management said fourth-quarter 2025 adjusted revenue would have been approximately $206.7 million, compared with an adjusted $188.6 million in fourth-quarter 2024.
Despite the revenue adjustment, management emphasized cash collections. Vo said operating cash flow remained strong, with net cash provided by operating activities of $70.4 million in the fourth quarter, compared with $0.1 million in the prior-year quarter. Bates added the company collected more than $207 million in hospital receipts during the quarter.
IDR process: submission rates, win rates, and ineligible claims
Management described IDR as a normalized part of its revenue cycle, with Vo stating that 50% to 60% of claims are submitted through IDR. When determinations are issued, Nutex said it prevails in over 85% of cases and is realizing an average cash collection rate of more than 85% on wins. Bates put arbitration costs at roughly 26% of arbitration-related revenue.
Vo said the approximately 18,950 ineligible claims equate to about 1,050 charts per month and cited HaloMD, the company’s IDR consultant, estimating Nutex’s ineligible rate at roughly 8% of submitted charts, below an industry figure management cited near 19%. Bates said the company disagrees with some ineligibility determinations and is challenging a portion of them; any favorable outcomes would be recorded as revenue in future periods.
On the analyst Q&A, management addressed an apparent shift in the IDR submission rate cited across prior commentary and the press release. Bates said the company’s goal is to resolve claims earlier—through open negotiations or contracts—rather than push them to IDR, and he characterized the trend toward lower submission rates and improved collections as positive. Vo added the dynamics can vary by quarter and said the direction suggests payers may be paying more appropriately up front.
Asked when Nutex learned about the fourth-quarter true-up, Bates said the earliest indications came in the middle of the fourth quarter, but the company needed time to analyze the impact and legitimacy of the determinations. On future true-ups, he said they could occur in any period and that Nutex intends to account for such items as soon as they are known, incorporating new data into its accrual model.
Balance sheet, cash position, and capital allocation priorities
Nutex ended 2025 with $185.6 million in cash and cash equivalents, up from $40.6 million a year earlier. Net cash from operating activities rose to $248.1 million for the year, compared to $23.2 million in 2024. Accounts receivable increased to $319.4 million at year-end from $232.4 million, which Bates said management remains confident in given consistent collections.
Total bank debt was $43.5 million at year-end 2025, up slightly from $41.4 million, which Bates said was primarily equipment financing for items such as MRI, CT, and other imaging tools. Vo noted that the current portion of long-term debt declined slightly year over year, while net long-term debt increased to $29.2 million, which he characterized as low relative to revenue and expansion.
Vo outlined four capital allocation priorities:
- Share repurchases: Nutex launched a $25 million repurchase program in late 2025 and completed it in early 2026, and authorized an additional $25 million program.
- Growth at existing hospitals: Investments in ER and inpatient initiatives, including service lines such as medical detox, behavioral health, outpatient imaging, outpatient procedures, and personal injury services, as well as enhanced equipment and expanded telehospitalist and telespecialist coverage.
- Expansion of IPAs and population health: Plans to expand independent physician associations around hospital markets to support referrals and positioning for value-based reimbursement.
- Real estate development strategy: Evaluating a model where Nutex develops and owns facilities through stabilization and may later execute sale-leaseback transactions to recycle capital.
Operations, population health, and expansion plans
President Dr. Warren Hosseinion said the population health management division oversees approximately 40,000 members across Medicare Advantage, commercial, and Medicaid managed care. He reported that each of Nutex’s four operational IPAs was profitable in 2025. The company launched a new IPA in Phoenix in 2025 and plans to launch two IPAs in 2026—Dallas and San Antonio—focused on network expansion, value-based contract growth, and technology scaling.
COO Wesley Bamburg said Nutex broadened service offerings and standardized workflows, staffing models, and intake/triage processes to support higher throughput. He said expanded specialized equipment and telespecialist capabilities helped retain higher-acuity patients, reduce avoidable transfers, and support contribution margins. Bamburg also said that excluding arbitration expenses, operational costs were 33.4% of total revenue in 2025, down from 47.1% in 2024, citing centralized supply chain and purchasing efforts that improved vendor pricing for major imaging equipment and lab supplies.
On patient experience, Bamburg said Nutex received more than 8,700 patient reviews in 2025 with an average enterprise rating of 4.8 out of five.
Vo said Nutex operates 27 hospital facilities across 12 states and opened hospitals in Sherman, Texas; St. Louis, Missouri; and Humble, Texas in 2025 and early 2026. In response to a question about Humble, Vo said the facility had previously closed during the No Surprises Act disruption and was reopened after IDR-related reimbursement improved and as the company strengthened its inpatient capabilities.
Looking ahead, Vo said three locations are on track to open in 2026—Jacksonville, West Little Rock, and San Antonio—targeting construction completion around the third quarter. He also discussed a pipeline for 2027 and 2028, with a projection of about four hospital openings in 2027 and another four after that, while noting the real estate strategy remains under discussion and not yet formalized.
About Nutex Health (NASDAQ:NUTX)
Nutex Health, Inc (NASDAQ: NUTX) is an integrated outpatient healthcare services company based in San Antonio, Texas. The company focuses on delivering a range of ambulatory care solutions, including urgent care, telemedicine, medical imaging, teleradiology, weight‐loss services and behavioral health support. By combining in‐person clinics with virtual care capabilities, Nutex Health aims to provide patients with accessible, cost‐effective treatment options outside traditional hospital settings.
The company’s urgent care network operates through both standalone and retail‐anchored centers, offering treatment for non‐life‐threatening injuries and illnesses, preventive screenings and basic primary care.
Featured Articles
- Five stocks we like better than Nutex Health
- BNZI stands out as a Zacks Buy. Earnings momentum and analyst upgrades align
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- What a Former CIA Agent Knows About the Coming Collapse
- Your name isn’t on our protected list yet
- What Expenses Can Be Deducted From Capital Gains Tax This Year?
